目的 采用文献计量学方法，系统梳理粉防己碱的研究现状，识别研究热点与趋势，为后续研究提供参考。方法 以中国知网（CNKI）和Web of Science为数据源，检索1982—2025年粉防己碱相关中英文文献，运用CiteSpace 6.3.R1与VOSviewer 1.6.20软件对发文趋势、国家、机构、作者及关键词进行可视化分析。结果 共纳入文献1 480篇（中文742篇，英文738篇）。英文文献量逐年上升，中文文献量趋于稳定；中国、美国、日本为发文量前3国家；国内外核心作者分别为饶曼人、李庆平与Xu Wencheng、Hirano Toshihiko；研究机构以高校为主，国际合作较弱。关键词分析显示，粉防己碱研究集中于药理作用（如抗肿瘤、抗纤维化）、机制（如细胞凋亡、自噬）及新型制剂（如脂质体、纳米递送系统）。突现词提示近年来研究热点向乳腺癌、增殖、固体脂质纳米粒等方向转移。结论 粉防己碱研究受国际关注，药理机制与新型制剂是当前研究重点，未来应在跨机构合作、智能递送系统及多组学机制阐释等方面深入探索。

Objective To systematically review the research status of tetrandrine, identify research hotspots and trends, and provide references for future studies through bibliometric analysis. Methods Literature related to tetrandrine published between 1982 and 2025 was retrieved from CNKI and Web of Science. CiteSpace 6.3.R1 and VOSviewer 1.6.20 were used to visualize annual publications, country/region distribution, institutions, authors, and keywords. Results A total of 1 480 articles (742 in Chinese, 738 in English) were included. The number of English publications showed an increasing trend, while Chinese publications remained stable. China, the United States, and Japan were the top three contributing countries. The core authors were Rao Manren and Li Qingping in Chinese publications, and Xu Wencheng and Hirano Toshihiko in English publications. Research institutions were mainly universities, with limited international collaboration. Keyword analysis indicated that research on tetrandrine focused on pharmacological effects (antitumor, antifibrotic), mechanisms (apoptosis, autophagy), and novel formulations (liposomes, nano-delivery systems). Emerging keywords suggested recent shifts toward breast cancer, proliferation, and solid lipid nanoparticles. Conclusion Tetrandrine research has gained international attention, with pharmacological mechanisms and novel formulations being current hotspots. Future studies should strengthen cross-institutional collaboration, develop intelligent delivery systems, and elucidate multi-omics mechanisms.

G350;R283;R285

国家自然科学基金资助项目（82174065）；云南省朱兆云院士工作站（202405AF140128）；云南省科技厅社会发展专项-重点研发计划项目（202303AC100025）；国家中医药管理局“十二五”重点学科—傣药学；云南省教育厅科学研究基金项目（2024Y379）；云南省中西医结合慢病防治重点实验室开放基金资助项目（YPKLG2024-016）；云南省傣医药与彝医药重点实验室资助项目（2024SS24074）